Patient-Derived Xenograft Model Market Report - Forecast 2030

Patient-Derived Xenograft Model Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Model Type (Mice Models and Rats Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, and Other Tumor Models), Application (Preclinical Drug Development, Biomarker Analysis, Translational Research, and Biobanking), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Government Research Institutions), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

Publication Month : Feb 2024

  • Report Code : TIPRE00021693
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[Research Report] The patient-derived xenograft model market size is projected to grow from US$ 378.46 million in 2022 to US$ 975.31 million by 2030; it is estimated to record a CAGR of 12.6% during 2022–2030.

Market Insights and Analyst View:

The patient-derived xenograft (PDX) model refers to laboratory models that are created by implanting patient tumor tissues directly into immunodeficient mice. These models are used in preclinical research to study the behavior of tumors and evaluate the efficacy of potential therapies. The market is expected to exhibit a promising performance over the next decade. Driven by elevating investments in cancer research and rising demand for personalized medicine, the adoption of PDX models is likely to surge significantly. As drug developers strive to improve their clinical success rates, PDX models are becoming a valuable tool due to their ability to mimic human tumor behavior and suitability for therapy response prediction studies, which favor the growth of the patient-derived xenograft model market

Growth Drivers:

Mice that are immunocompromised are now reconstituted with bone marrow or peripheral blood cells and patients’ tumor implants to create humanized xenograft models. Humanized models can be utilized to study the role of xenogeneic immune cells in overall anti-cancer immunity. Humanized models also help in the development of immunotherapy drugs. However, in humanized mice models, there is a risk of graft vs. host disease, which may hamper the outcomes of stroma-tumor interaction evaluation studies. These interactions are essential for tumor growth and progression in patients. Humanized models engrafted with PDX offer a promising approach to oncology research, providing an improved understanding of human tumors and accelerating the development of personalized treatments. PDX models offer numerous advantages, including the depiction of the patient’s tumor microenvironment and its diversity, the detection of therapeutic targets, the determination of the potential for developing personalized therapies, and the interaction with a complete human immune system. Humanized patient-derived xenograft models help overcome the humanized mice models' drawbacks and are gaining demand in the market. For example, Champions Oncology has developed more than 1,500 diverse tumor models from various patients in the primary or metastatic phase. Thus, the growing awareness regarding the benefits of humanized PDX models boosts the patient-derived xenograft model market growth during the forecast period.

Moreover, the patient-derived xenograft model market trends include the development of next-generation PDX technologies and ongoing research studies for drug development.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Patient-Derived Xenograft Model Market: Strategic Insights

patient-derived-xenograft-models-market
Market Size Value inUS$ 378.46 million in 2022
Market Size Value byUS$ 975.31 million by 2030
Growth rateCAGR of 12.6% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The patient-derived xenograft model market analysis has been carried out by considering the following segments: model type, tumor type, application, end user, and geography. Based on model type, the market is categorized into mice models and rats models. In terms of tumor type, the patient-derived xenograft model market is classified into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, and other tumor models. The market, by application, is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and government research institutions, and contract research organizations.

The scope of the patient-derived xenograft model market report covers North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The patient-derived xenograft model market, by model type, is bifurcated into mice models and rats models. The mice models segment held a significant market share in 2022. It is anticipated to record a higher CAGR in the market during 2022–2030.

Based on tumor type, the market is segmented into gastrointestinal tumor models, respiratory tumor models, gynecological tumor models, and other tumor models. In 2022, the other tumor model segment held a significant share of the market and is projected to register the fastest CAGR during 2022–2030.

Based on application, the market is categorized into preclinical drug development, biomarker analysis, translational research, and biobanking. The preclinical drug development segment held a significant patient-derived xenograft model market share in 2022. The segment is estimated to register the highest CAGR during 2022–2030.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and academic and government research institutions. The academic and government research institutions segment held a significant patient-derived xenograft model market share in 2022. It is expected to register the highest CAGR during 2022–2030.

Patient-Derived Xenograft Model Market, by Model Type– 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Regional Analysis:

Based on geography, the patient-derived xenograft model market report is primarily divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. In 2022, the US held the largest share of the market in the region. The market growth in North America is attributed to the availability of modern healthcare infrastructure, the strong presence of key market players, the growing number of cancer cases, and rising investments by the government and private sectors. As per the Centers for Disease Control and Prevention, in 2020, ~239,612 new cases of breast cancer were reported among women in the US, while ~42,273 succumbed to death due to this disease. For every 100,000 women, 119 new breast cancer cases were reported in women, of which nearly 19 have died. As per the breast cancer statistics by the Breast Cancer Organization, about 1 in 8 women (i.e., 12%) develops invasive breast cancer in their lifetime. Moreover, as breast cancer is the most prevalent cancer in Canadian women and the second leading reason for cancer deaths, there is a high demand for efficient diagnosis options. According to the Canadian Cancer Society, ~28,600 women were diagnosed with breast cancer in 2022 in the country, accounting for ~25% of the total new cancer cases in women. With growing cancer cases, the need to develop suitable treatment arises, which propels the growth of the patient-derived xenograft model market.

According to an article published in April 2022 by Oncoimmunology, researchers used the diversity outbred (DO) and collaborative cross (CC) mouse models to study the outcomes of the immune checkpoint inhibitors against various tumors. For this study, the researchers purchased the DO mice models from the Jackson Laboratory and CC mice from the Systems Genetics Core Facility at the University of North Carolina. Thus, the growing research and the use of mouse models for anticancer drug discovery propels the patient-derived xenograft model market growth in the region.

Industry Developments and Future Opportunities:

Initiatives taken by market players operating in the global patient-derived xenograft model market are listed below:

  • In July 2022, GemPharmatech entered a strategic licensing arrangement with Charles River Laboratories. The partnership involves the exclusive distribution rights for GemPharmatech's next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines within North America.
  • In November 2021, Inotiv Inc. completed the acquisition of Envigo RMS Holding Corp., a globally leading provider of research models and services.

Competitive Landscape and Key Companies:

The patient-derived xenograft model market forecast can help stakeholders plan their growth strategies. Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation are among the prominent players in the market. The market players focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Model Type, Tumor Type, Application, End User, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment is dominating the patient-derived xenograft model market?

The global patient-derived xenograft model market is segmented based on model type, tumor type, application, and end user. The patient-derived xenograft model market, by model type, is categorized into mice models and rats models. The mice models segment held a significant share of the market in 2022 and is expected to register a higher CAGR in the market during 2022–2030.

What was the estimated patient-derived xenograft model market size in 2022?

The patient-derived xenograft model market was valued at US$ 378.46 million in 2022.

What are the growth estimates for the patient-derived xenograft model market till 2030?

The patient-derived xenograft model market is expected to be valued at US$ 975.31 million in 2030.

Who are the major players in the patient-derived xenograft model market?

The patient-derived xenograft model market majorly consists of the players, including Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation.

What is patient-derived xenograft model?

The patient-derived xenograft (PDX) model refers to laboratory models that are created by implanting patient tumor tissues directly into immunodeficient mice. These models are used in preclinical research to study the behavior of tumors and evaluate the efficacy of potential therapies.

What is the driving and restraining factors for the patient-derived xenograft model market?

The factors driving the growth of the patient-derived xenograft model market include the growing awareness of the advantages of humanized PDX models and the rising demand for personalized medicine. However, significant operational costs associated with the PDX model hampers the growth of the patient-derived xenograft model market.

The List of Companies - Patient-Derived Xenograft Model Market

  1. Champions Oncology Inc.
  2. Charles River Laboratories Inc.
  3. Crown Bioscience Inc.
  4. EPO Berlin-Buch GmbH
  5. Hera BioLabs
  6. Horizon Discovery Group plc
  7. Oncodesign
  8. Pharmatest Services Ltd
  9. Xentech SAS
  10. JSR Corporation.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Patient-Derived Xenograft Model Market